Abstract: The present disclosure is directed to a method for reducing power consumption of a sensor. The method includes determining if a predetermined condition has been met to change at least one of a sensing rate or a sensor resolution, and changing at least one of the sensing rate or sensor resolution if it is determined that the predetermined condition has been met.

Abstract: Systems, and methods for controlling a modular system for improved real-time yield monitoring and sensor fusion of crops in an orchard are disclosed. According to some embodiments of the invention, a modular system for improved real-time yield monitoring and sensor fusion may include a collection vehicle, a modular processing unit, a volume measurement module, a three-dimensional point-cloud scanning module, an inertial navigation system, and a post-processing server. As the collection vehicle travels through an orchard, the volume measurement module calculates volume measurements of the windrow, the three-dimensional point-cloud scanning module assembles point-clouds of each plant in the orchard, and the inertial navigation system calculates geodetic positions of the collection vehicle. The modular processing unit may fuse the collected data together and transmit the fused data set to a post-processing server.

Abstract: An egg flat identification system for identifying an egg flat among a collection of egg flats is provided. Such a system includes a first measurement device configured to determine a first measurement of a plurality of eggs carried by an egg flat. A processor is in communication with the first measurement device. The processor is configured to receive the first measurements from the first measurement device. A second measurement device is configured to determine a second measurement of the eggs in the collection of egg flats. The second measurement device is in communication with the processor such that the processor is capable of receiving the second measurements. The processor compares the second measurements with the first measurements so as to identify a respective egg flat among the collection of egg flats.

Abstract: An in-cylinder pressure sensor is provided. It is determined whether a cylinder for which the in-cylinder air-fuel ratio is to be calculated is a rich cylinder or a lean cylinder. A polytropic index in the expansion stroke is calculated from the in-cylinder pressure detected by the in-cylinder pressure sensor. The calculated polytropic index m is corrected based on an operational condition parameter of an internal combustion engine. An in-cylinder air-fuel ratio is calculated based on the corrected polytropic index m in the expansion stroke, the result of the determination of whether the cylinder is a rich cylinder or a lean cylinder, and an m-A/F curve.

Abstract: A method for estimating a fracability index for a geological location includes determining a fabric metric and a mineralogical composition metric for a geological sample extracted from a geological location and estimating a fracability index for the geological location from the fabric metric and the mineralogical composition metric. The fabric metric may be a grain related measurement such as grain size or angularity, or a pore-space related measurement such as pore area, diameter, aspect ratio, and circumference, or statistics associated with such measurements. In certain embodiments, determining the mineralogical composition metric includes detecting a prevalence of at least one organic proxy within the geological sample such as vanadium, iron, uranium, thorium, copper, sulfur, zinc, chromium, nickel, cobalt, lead and molybdenum. Determining the mineralogical composition metric may also include detecting a prevalence of one, two, or all of siliciclastics, carbonate and clay.

Abstract: A measuring device is embedded in a section of concrete at a location at a construction site, the measuring device being adapted to obtain a measurement of a first characteristic of the section of concrete and transmit the measurement via wireless transmission. The first characteristic may include temperature, humidity, conductivity, impedance, salinity, etc. A local wireless gateway receives the measurement data and transmits the data to a processor. Alternatively, an airborne drone flying above the construction site receives the measurement data and transmits the data to the processor. The processor generates a predicted second characteristic of the section of concrete based on the measurement data. For example, the second characteristic may include strength, slump, age, maturity, etc., of the concrete.

Abstract: Embodiments described herein are directed to devices for supporting growth of anisotropic muscle tissue layers and in vitro readout and quantification of force generated by the tissue layers using one or more strain-sensing elements integrated into the device. Embodiments also include multiplexed apparatuses of multiple independent devices, methods of fabricating the devices and apparatuses, and methods of using the devices and apparatuses.

Abstract: An analyte testing material web, method of making the analyte testing material web, and an analyzer are disclosed. The analyte testing material web has a material web and a plurality of distinct sample testing devices. The material web has a first surface, a second surface opposite the first surface, a first side, and a second side. The plurality of sample testing devices are positioned on the first surface of the material web. Each of the plurality of sample testing devices has an inlet, an outlet, a fluid channel, and one or more testing elements within the fluid channel and configured to analyze one or more analyte within a sample applied to the inlet of one of the plurality of sample testing devices.

Abstract: Systems and methods for specific nucleic acid (NA) sequence detection that do not rely on polymerase chain reaction (PCR) for target sequence amplification and do not require any special reagents other than a complementary sequence capture probe conjugated to spherical beads.

Abstract: An acoustical non-contact levitation system and method for eliciting the deformation response of biological samples, coupled with the data analysis to yield quantitative measures of established time-dependent viscoelastic material properties. Embodiments allow for measurement to occur in near-real-time by way of a computer. In use, a biological sample is placed in an acoustic levitator, where it is induced to oscillate, such that material properties of the sample can be observed and analyzed by way of a camera and/or photodiode.

Abstract: The present invention provides novel methods of cell staining, such as bovine sperm, using electroporation or osmolality treatments at viability-enhancing temperatures. Furthermore, methods of highly efficient cell sorting that are especially suitable in sorting bovine sperm using novel cell staining procedures are also provided.

Abstract: The present invention aims to provide a novel compound for measuring cellular cytotoxicity or cell proliferation capacity accurately with high reproducibility, conveniently and rapidly, and a measurement method of cellular cytotoxicity or cell proliferation capacity by using the compound. The present invention relates to a compound represented by the formula (I): wherein R1 is a substituent, R2 and R3 are each an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, Y is a substituent, n is an integer of 0-3, Z is a single bond, —O—, —S—, —SO—, —SO2—, or —NR4— (R4 is a hydrogen atom or a substituent), and A is an optionally substituted C1-6 alkylene group) or a salt thereof.

Abstract: A method to identify a candidate compound for use in the treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal, by identifying a candidate compound that causes an increase in translocation of GLUT without causing an increase in the production of cAMP. A kit for use in such a method. A method of treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal and a compound for use in such a method.

Abstract: Early warning of changing health and robustness is given by tracking of ease of morphological changes in blood cells obtained by comparing intensities in a first scattered light intensity angular distribution and intensities in a second scattered light intensity angular distribution, with the light being scattered by blood cells into very narrowly forward scattered light intensity angular range.

Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.

Abstract: The present invention is directed to creating a highly versatile, high throughput, and convenient platform for interrogating migration phenotypes of GB cells in the context of diverse environmental parameters. Specifically, engineered substrates are employed to mimic the mechanical signals of natural ECM topography, and combine these tools with chemical cues presented in soluble and immobilized forms (PDGF and laminin, respectively). This platform achieves far greater resolution and sensitivity in migration analyses than do commonly used methods. More importantly, it can provide highly informative, patient specific results regarding tumor progression in vivo. Furthermore these capabilities strongly convey the immense clinical, prognostic potential of this simple test.

Abstract: Provided are compositions and methods employing cells encapsulated within and attached to a hydrogel, e.g., for measuring mechanical strain and/or stress of the cell and for investigating the mechano-chemo-transduction mechanisms at cellular and molecular levels.

Abstract: The present invention relates to an induced pluripotent stem cell (iPSC) model of Noonan syndrome, a preparation method thereof, and uses to study of the pathogenesis of Noonan syndrome and a therapeutic agent screening method. Particularly, induced pluripotent stem cells from dermal fibroblasts of a Noonan syndrome-patient (NS-iPSCs) were generated, and differentiated into embryoid bodies (EBs), neural rosettes and neural cells. These iPSCs exhibited the normal morphology while showed reduced differentiation potency compare to control cell lines. NS-iPSCs were developed into embryoid bodies and neural rosettes by naturally and chemically directed differentiation. Interestingly, embryoid bodies and neural rosettes induced via chemically directed differentiation exhibited normal morphology and expressed ectoderm, neural rosettes and neural marker genes similar to normal cells.

Abstract: Disclosed are an enhancement solution for enhancing chemiluminescence, and a method for preparing a chemiluminescent solution. The method comprises Step A: dissolving methylglucamine in water, adjusting the pH to 8-9, then adding an N-alkyldimethylmannosamine quaternary ammonium salt, acridine orange, BSA, glycine, MgCl2, and ZnCl2 respectively to a diethanolamine solution, stirring to dissolve them, and diluting to a constant volume, to obtain an enhancement solution; and Step B: diluting a chemiluminescent substrate with the enhancement solution, to obtain a chemiluminescent solution. When used in the field of immunoassays, the enhancement solution of the present invention increases the sensitivity and linear range of detection, reduces the cost, and is free of contamination.

Abstract: The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula I. For example, the invention provides methods for labeling the N-terminus of a protein that terminates with a cysteine residue. The invention also provides methods for isolating an N-terminally labeled protein and methods for detecting an N-terminally labeled protein.

Abstract: A device is provided for detecting amplified products of nucleic acid, the device can detect at least one analyte molecule comprising a first marker and a second marker. This device sequentially comprises the following sections along an axial direction: a sample contact section where the analyte molecule is absorbed, a combining section where the analyte molecule is received comprises a reporting carrier specifically bound with the first marker, and a detecting section comprises at least one color reaction section comprising a control unit point having a first combining molecule for specifically binding with the reporting carrier and presenting color, and at least one testing unit point having a second combining molecule for specifically binding with the second marker and presenting color. The control unit point and the testing unit point are separated from each other, and a line connecting them is not parallel to the axial direction.

Abstract: The invention relates to a method for quantitatively determining biological analytes in an aqueous solution in the presence of one or more functionalised surfaces, wherein the aqueous solution comprises at least one type of biological analyte and at least one type of fluorescence marker, characterised in that the quantity and/or concentration of the biological analyte or analytes is determined by measuring the fluorescence emission of the unbound fluorescence markers, as well as to a devices for carrying out said method.

Abstract: The present invention relates to diagnostic devices as well as methods of using these devices for detecting proteins of interest associated with diseases or disorders in mammals. In particular, the proteins of interest may be misfolded proteins associated with certain misfolded-protein disorders in mammals including those mammals suspected of or at risk of having such disorders.

Abstract: A biomarker sensor using short peptide recognition elements. The biomarker sensor includes a substrate and a metallic layer on a surface of that substrate that is localized surface plasmon resonance reactive. A receptor layer on the surface of the metallic layer (the surface opposing the substrate) is configured to selectively bind a biomarker and has a thickness less than about 15 nm.

Abstract: The present invention relates to a method of preparing a molecular sensor that is specific for a target molecule having a saccharide or peptide region. The method comprises using the target molecule as a template and incubating the template with a receptor to form a template-receptor complex. A molecular scaffold is formed on a surface around the template-receptor complex such that the receptor and at least a portion of the template are embedded in the scaffold, and the template is removed to produce a cavity defined by the scaffold, such that the cavity is complementary to at least a portion of the saccharide or peptide region of the target molecule.

Abstract: The present invention relates to a method for detecting a target molecule, comprising forming a capturing complex comprising the target molecule; and binding the capturing complex with a signal amplifier, wherein the capturing complex has a net electrical charge; the signal amplifier has affinity to the capturing complex and has a like net electrical charge of the net electrical charge of the capturing complex. The invention improves the detection sensitivity and sensing limit of the detection.

Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.

Abstract: Biomarkers useful for assessing inflammatory disease or flare activity, in particular in juvenile idiopathic arthritis, are provided, along with kits for measuring expression of the biomarkers. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.

Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.

Abstract: This invention relates to a cell-surface marker for identifying MSC that are aging. This invention also relates to a method of screening MSCs of low proliferation potential and trilineage potential by removing CD264+ MSCs from the population.

Abstract: Provided herein is a method of detecting the presence of influenza virus in a sample while minimizing false positives due to presence of one or more other pathogens in the sample, the method including measuring the enzymatic activity of neuraminidase (NA) in the sample under one or more differentiating conditions selected from the group consisting of pH, binding to anti-NanA antibody, size exclusion, hemagglutinin (HA) binding, chemical inhibition, and combinations thereof.

Abstract: The present invention provides a method of diagnosing and treating Graft versus host disease (GVHD), said method comprising: a. obtaining a body fluid or tissue sample from said mammal, throughout the year post-transplant; b. detecting the expression level, phosphorylation level, or a combination thereof, of biomarkers in said body fluid or tissue sample; c. diagnosing said mammal with Graft versus host disease (GVHD) when the expression level, phosphorylation level, or a combination thereof of said biomarkers in said body fluid or tissue sample are detected with a deviation of at least about 25% from standard measurements taken from healthy subjects and/or from measurements taken from said mammal prior to said transplant; and, d. administering an effective amount of at least one immunosuppressant or steroid or a combination thereof to the diagnosed mammal.

Abstract: It is an object to provide a simplified early diagnosis method for breast cancer, wherein a sample collected from a human subject is analyzed and determination of the presence or absence of breast cancer is made from the proportion of plural types of polyamines including N1-acetylspermidine.

Abstract: The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AMLI-ETO acetylation. The present invention further provides methods of using these treatments.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for identification of individuals having clinically significant cancer. In one embodiment, a method for treating a subject having prostate cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to measure the levels of one or more protein biomarkers listed in Table 1; (c) comparing the measured levels of one or more protein biomarkers to one or more reference controls to identify the subject as having high grade prostate cancer, low grade prostate cancer or no prostate cancer; and (d) treating the subject with one or more treatment modalities appropriate for a subject having high grade prostate cancer or low grade prostate cancer.

Abstract: The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

Abstract: A cancer detection method characterised in that a nematode is bred in the presence of bio-related material originating from a test subject, or a processed product of same, and cancer is detected using the chemotaxis due to the sense of smell of the nematode as an indicator.

Abstract: The invention relates to novel luminescent compositions of matter containing two fluorophores (sensitizers), synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions and their conjugates in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection.

Abstract: The present invention relates to a metabolic biomarker set for assessing kidney disease comprising at least two amino acids, at least two acylcarnitines and at least two biogenic amines. Moreover, the present invention relates to a method for assessing kidney disease in a mammalian subject which comprises obtaining a biological sample, preferably blood and/or urine, from the subject and measuring in the biological sample the amount of at least two amino acids, of at least two acylcarnitines and of at least two biogenic amines, as well as to a kit adapted to carry out the method. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess kidney disease.

Abstract: The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Abstract: Provided is a method for measuring a target polypeptide in a biological sample abundantly containing impurities by mass spectrometry.

Abstract: The present invention provides a method capable of more accurately quantifying a biological material expressed on the cell membrane in pathological samples. The present invention is directed to a method for quantifying a biological material (target biological material) expressed on the cell membrane, the method including the steps of: (1a) immunostaining the target biological material with a fluorescent material; (1b) immunostaining another biological material (reference biological material) on the cell membrane with another fluorescent material; (2) using immunostaining images for the target and reference biological materials to identify the fluorescence signal corresponding to the target biological material and to measure the fluorescence signals corresponding to the target and reference biological materials; and (3) correcting the measured value of the fluorescence signal corresponding to the target biological material by a given method to quantify the expression level.

Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring heme, oxygen or ATP. Biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest. Model cells expressing the biosensors can be contacted with putative bioactive agents to determine possible activities.

Abstract: A method of determining the osteoarthritis, inflammatory arthritis or joint injury status in a subject, and a panel of test biomarkers for use in determining same is disclosed. In particular, the method comprise the steps of determining the expression levels of at least three test biomarkers in a sample of bodily fluid obtained from the subject; conducting a statistical analysis of the correlation and relative expression levels between the at least three biomarkers; calculating a statistical score based on the statistical analysis; and comparing the statistical score with reference statistical scores generated from at least three reference group expression profiles to predict, diagnose, monitor or determine one or more of osteoarthritis, inflammatory arthritis or joint injury. For both the method and panel the test biomarkers typically contains at least PIIANP. By analysis of the test biomarkers, the disease status of a subject may be determined.

Abstract: The invention relates to a biomarker useful for the diagnosis of kidney disease and for determining patients whose disease severity level is likely to progress. The invention provides methods and products for determining the propensity for kidney disease progression.

Abstract: The present disclosure provides methods of screening and compositions and methods for treating ciliopathy diseases. Methods are provided for screening for molecules to treat ciliopathy disorders by measuring the activity of ubiquitin-proteasome system (UPS)-mediated protein degradation in the presence and the absence of a candidate molecule, wherein an increase of the activity in the presence of the candidate molecule identifies the molecule as a potential therapeutic. The methods provided also include measuring the activity of a ubiquitin peptidase or a Zic family member 1 (ZIC1) gene product, in the presence and absence of a candidate molecule, wherein a decrease in activity in the presence of the molecule identifies it as a potential therapeutic.

Abstract: A method for analyzing concentration of a cardiovascular disease (CVD) biomarker in a liquid sample includes: applying the liquid sample to a biosensor, the biosensor including a transistor having a drain, a source, and a gate terminal disposed between the gate and the source, and a reactive electrode spaced apart from the gate terminal of the transistor and having a receptor immobilized thereon for specific binding with the CVD biomarker, the liquid sample being in contact with the gate terminal and the reactive electrode; applying a voltage pulse between the reactive electrode and the source, the voltage pulse having a pulse width; monitoring a response current in response to the voltage pulse; and analyzing the response current.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock 70 kDa protein 1, Alpha-1-antitrypsin Neutrophil elastase complex, Stromelysin-1:Metalloproteinase inhibitor 2 complex, 72 kDa type IV collagenase:Metalloproteinase inhibitor 2 complex, Insulin-like growth factor 1 receptor, Myeloid differentiation primary response protein MyD88, Neuronal cell adhesion molecule, and Tumor necrosis factor ligand superfamily member 10 as diagnostic and prognostic biomarkers in renal injuries.

Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.